JulianRMolinaMD

Oncology • Rochester, MN

Assistant Professor, Oncology, Mayo Medical School

Join to view full profile

Dr. Molina is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Molina's full profile

Already have an account?

Office
200 1st Street SW
Rochester, MN 55905
Is this information wrong?

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2000 - 2004
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 1997 - 2000
Pontifical Bolivarian UniversityClass of 1982

Certifications & Licensure

MN State Medical License 2001 - 2024

Clinical Trials

R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer Start of enrollment: 2002 Nov 01
Completed
Phase 2
Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors Start of enrollment: 2004 May 20
Completed
Phase 1
Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2004 Dec 01
Completed
Phase 2
Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2006 Feb 01
Completed
Phase 2
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors Start of enrollment: 2007 Jan 25
Completed
Phase 1
Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2006 Nov 01
Completed
Phase 2
Gold Sodium Thiomalate in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2007 Jan 25
Completed
Phase 1
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer Start of enrollment: 2003 Apr 01
Completed
Phase 2
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Start of enrollment: 2004 Dec 01
Completed
Phase 1
Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524 Start of enrollment: 2006 Nov 01
Completed
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2010 Jan 01
Terminated
Phase 2
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy Start of enrollment: 2010 Apr 01
Completed
Phase 2
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery Start of enrollment: 2010 Dec 01
Completed
Phase 1
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Validation of the MiCK Assay Start of enrollment: 2012 Jun 01
Terminated
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy Start of enrollment: 2015 Jun 29
Terminated
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing Start of enrollment: 2021 Oct 29
Recruiting
Join now to see all

Publications & Presentations

PubMed

4 citations
Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
Aakash Desai, Caleb J Smith, Yash Ashara, Jacob J Orme, Saurabh Zanwar, Ashley Potter, Craig Hocum, J Nicole Moffett, Anna J Schwecke, Rami Manochakian, Yanyan Lou, Yu...> ;Clinical Lung Cancer. 2023 Dec 1
5 citations
Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report.
Aakash Desai, Sagar Rakshit, Radhika Bansal, Yash Ashara, Ashley Potter, Rami Manochakian, Yanyan Lou, Yujie Zhao, Vinicius Ernani, Panos Savvides, Anna Schwecke, Nico...> ;Cancer Treatment and Research Communications. 2023 Jan 1
4 citations
EZH2 and POU2F3 Can Aid in the Distinction of Thymic Carcinoma from Thymoma.
Julia R Naso, Julie A Vrana, Justin W Koepplin, Julian R Molina, Anja C Roden> ;Cancers. 2023 Apr 13
Plasma Biomarkers to Monitor Bronchopulmonary Carcinoids-Are We There Yet?
Anja C Roden, Julian R Molina> ;Journal of Thoracic Oncology. 2023 Mar 1
1 citations
Correction to: PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma.
Prabhu Thirusangu, Upasana Ray, Sayantani Sarkar Bhattacharya, Derek B Oien, Ling Jin, Julie Staub, Nagarajan Kannan, Julian R Molina, Viji Shridhar> ;Oncogene. 2023 Jan 1
18 citations
PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma.
Prabhu Thirusangu, Upasana Ray, Sayantani Sarkar Bhattacharya, Derek B Oien, Ling Jin, Julie Staub, Nagarajan Kannan, Julian R Molina, Viji Shridhar> ;Oncogene. 2022 Aug 1
6 citations
PFKFB3 works on the FAK-STAT3-SOX2 axis to regulate the stemness in MPM.
Sayantani Sarkar Bhattacharya, Prabhu Thirusangu, Ling Jin, Julie Staub, Viji Shridhar, Julian R Molina> ;British Journal of Cancer. 2022 Oct 1
10 citations
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Ac...
D Ross Camidge, Teresa Moran, Ingel Demedts, Heidrun Grosch, Kathryn Mileham, Julian Molina, Oscar Juan-Vidal, Gerold Bepler, Jonathan W Goldman, Keunchil Park, Johan ...> ;Clinical Lung Cancer. 2022 Jun 1
3 citations
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis.
Fang Yang, Yucai Wang, Lin Tang, Aaron Scott Mansfield, Alex A Adjei, Konstantinos Leventakos, Narjust Duma, Jia Wei, Lifeng Wang, Baorui Liu, Julian R Molina> ;Frontiers in Oncology. 2022 Jan 1
17 citations
Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges.
Fang Yang, Jacqueline F Wang, Yucai Wang, Baorui Liu, Julian R Molina> ;Cancers. 2021 Dec 27
4 citations
Quinacrine Has Preferential Anticancer Effects on Mesothelioma Cells With Inactivating NF2 Mutations.
Derek B. Oien, Sayantani Sarkar Bhattacharya, Jeremy Chien, Julian R. Molina, Viji Shridhar> ;Frontiers in Pharmacology. 2021 Sep 21
7 citations
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
Bin Qiu, Kaican Cai, Chun Chen, Jun Chen, Ke-Neng Chen, Qi-Xun Chen, Chao Cheng, Tian-Yang Dai, Junqiang Fan, Zhaohui Fan, Jian Hu, Wei-Dong Hu, Yun-Chao Huang, Gening...> ;Translational Lung Cancer Research. 2021 Sep 1
1 citations
SATB2 Is Expressed in a Subset of Pulmonary and Thymic Neuroendocrine Tumors.
Julie A. Vrana, Jennifer M Boland, Simone B S P Terra, Hao Xie, Sarah M. Jenkins, Aaron S. Mansfield, Julian R. Molina, Stephen D. Cassivi, Anja C. Roden> ;American Journal of Clinical Pathology. 2021 Oct 13
11 citations
Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma
Xuefeng Leng, Shiyou Wei, Jiandong Mei, Senyi Deng, Zhenyu Yang, Zheng Liu, Chenglin Guo, Yulan Deng, Liang Xia, Jiahan Cheng, Kejia Zhao, Fanyi Gan, Chuan Li, Kenneth...> ;Translational Lung Cancer Research. 2021 Feb 1
7 citations
Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.
Jithma P Abeykoon, Xiaosheng Wu, Kevin E Nowakowski, Surendra Dasari, Jonas Paludo, S John Weroha, Chunling Hu, Xiaonan Hou, Jann N Sarkaria, Ann C Mladek, Jessica L P...> ;Blood. 2021 Jan 28
CRM1 inhibitor anti-tumor activity is enhanced with salicylates by S-phase arrest and impaired DNA-damage repair
Jithma P. Abeykoon, Xiaosheng Wu, Kevin E. Nowakowski, Surendra Dasari, Jonas Paludo, S. John Weroha, Chunling Hu, Xiaonan Hou, Jann N. Sarkaria, Ann C. Mladek, Jessic...> ;Blood. 2020 Nov 2
4 citations
Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
Dipesh Uprety, Thorvardur R. Halfdanarson, Julian R. Molina, Konstantinos Leventakos> ;Current Treatment Options in Oncology. 2020 Aug 29
64 citations
Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Syste...
Fang Yang, Svetomir N. Markovic, Julian R. Molina, Thorvardur R. Halfdanarson, Lance C. Pagliaro, Ashish V. Chintakuntlawar, Rutian Li, Jia Wei, Lifeng Wang, Baorui Li...> ;JAMA Network Open. 2020 Aug 3
15 citations
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer
Keith C. Bible, Michael E. Menefee, Chia Chi Josh Lin, Michael Millward, William J. Maples, Boon Cher Goh, Nina J. Karlin, Madeleine A. Kane, Douglas Adkins, Julian R....> ;Thyroid. 2020 Sep 8
11 citations
Immunotherapy in patients with autoimmune disease
Sagar Rakshit, Julian R. Molina> ;Journal of Thoracic Disease. 2020 Jul 29
42 citations
Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors
Ohad Oren, Eric H. Yang, Julian R. Molina, Kent R. Bailey, Roger S. Blumenthal, Stephen L. Kopecky> ;The American Journal of Cardiology. 2020 Jun 15
4 citations
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).
Kaushal Parikh, Sumithra J. Mandrekar, Katie Allen-Ziegler, Brandt L. Esplin, Angelina D. Tan, Benjamin Marchello, Alex A. Adjei, Julian R. Molina> ;The Oncologist. 2020 Jun 1
13 citations
Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma.
Patrick W. McGarrah, Konstantinos Leventakos, Timothy J. Hobday, Julian R. Molina, Heidi D. Finnes, Gustavo Figueiredo Marcondes Westin, Thorvardur R. Halfdanarson> ;Pancreas. 2020 Apr 1
35 citations
Distribution of Mediastinal Lesions Across Multi-Institutional, International, Radiology Databases
Anja C. Roden, Wentao Fang, Yan Shen, Brett W. Carter, Darin White, Sarah M. Jenkins, Grant M. Spears, Julian R. Molina, Eyal Klang, Mattia Di Segni, Jeanne B. Ackman,...> ;Journal of Thoracic Oncology. 2020 Apr 1
Surgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience.
William G. Breen, Yolanda I. Garces, Kenneth R. Olivier, Sean S. Park, Kenneth W. Merrell, Francis C. Nichols, Tobias Peikert, Julian R. Molina, Aaron S. Mansfield, An...> ;Frontiers in Oncology. 2020 Mar 24
Join now to see all

Abstracts/Posters

Risk Factors for Increased Length of Stay (LOS) in Patients with Hematological Malignancies Electively Admitted for Chemotherapy
Julian R Molina, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019